Literature DB >> 32991344

Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors.

Jennifer R Eads1, Diane Reidy-Lagunes2, Heloisa P Soares3, Jennifer A Chan4, Lowell B Anthony5, Thorvardur R Halfdanarson6, Boris G Naraev7, Edward M Wolin8, Daniel M Halperin9, Daneng Li10, Rodney F Pommier11, Jerome S Zacks12, Michael A Morse13, David C Metz14.   

Abstract

Patients with neuroendocrine tumors (NETs) and carcinoid syndrome experience diarrhea that can have a debilitating effect on quality of life. Diarrhea also may develop in response to other hormonal syndromes associated with NETs, surgical complications, medical comorbidities, medications, or food sensitivities. Limited guidance on the practical approach to the differential diagnosis of diarrhea in these patients can lead to delays in appropriate treatment. This clinical review and commentary underscore the complexity in identifying the etiology of diarrhea in patients with NETs. Based on our collective experience and expertise, we offer a practical algorithm to guide medical oncologists and other care providers to expedite effective management of diarrhea and related symptoms in patients with NETs.

Entities:  

Mesh:

Year:  2020        PMID: 32991344     DOI: 10.1097/MPA.0000000000001658

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  2 in total

1.  Case 2: A 66-Year-Old Man With Chronic Watery Diarrhea.

Authors:  Ji Eun Shin; Seo Yeon Youn; Younghoon Kim; MyungAh Lee; Se Jun Park
Journal:  J Korean Med Sci       Date:  2022-08-01       Impact factor: 5.354

2.  European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease.

Authors:  Simona Grozinsky-Glasberg; Joseph Davar; Johannes Hofland; Rebecca Dobson; Vikas Prasad; Andreas Pascher; Timm Denecke; Margot E T Tesselaar; Francesco Panzuto; Anders Albåge; Heidi M Connolly; Jean-Francois Obadia; Rachel Riechelmann; Christos Toumpanakis
Journal:  J Neuroendocrinol       Date:  2022-05-25       Impact factor: 3.870

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.